Medication Safety And Pharmacovigilance In Children And Older Adults: A Comprehensive Review

Ganesh Chavan; Rushikesh Gadekar; Komal Jadhav; Vitthal R. Gawade; Vijay R. Pawar

doi:10.5281/zenodo.21715844

Review Paper | Open Access
Volume 03 | Issue 07 | Article Id IJSRT/260307203

Medication Safety And Pharmacovigilance In Children And Older Adults: A Comprehensive Review
Ganesh Chavan * Rushikesh Gadekar Komal Jadhav Vitthal R. Gawade Vijay R. Pawar
Suyash College of Pharmacy Warud Bk, Jalna, Maharashtra

Abstract

Medication safety is a fundamental component of healthcare quality and patient safety, particularly in vulnerable populations such as children and older adults. These groups are at an increased risk of adverse drug reactions (ADRs), medication errors, and drug-related complications due to age-specific physiological characteristics, altered pharmacokinetics and pharmacodynamics, polypharmacy, comorbidities, and limitations in clinical evidence. Pediatric patients often require individualized dosing based on age, body weight, and developmental stage, while older adults frequently experience multiple chronic illnesses requiring complex medication regimens, increasing the likelihood of drug–drug interactions and inappropriate prescribing. Pharmacovigilance plays a pivotal role in identifying, assessing, understanding, and preventing adverse effects associated with medication use, thereby improving therapeutic outcomes and ensuring patient safety. This review provides a comprehensive overview of medication safety principles and pharmacovigilance practices in pediatric and geriatric populations. It discusses the unique pharmacological considerations, common causes of medication-related harm, risk factors contributing to adverse drug reactions, and the significance of spontaneous reporting systems in detecting medication safety signals. The review also highlights the role of healthcare professionals, caregivers, regulatory authorities, and patients in promoting safe medication practices through effective reporting, education, and multidisciplinary collaboration. Furthermore, it explores the impact of technological advancements, including electronic health records, clinical decision support systems, artificial intelligence, machine learning, mobile health applications, and big-data analytics, in strengthening pharmacovigilance activities and improving medication safety surveillance. Recent developments in global pharmacovigilance programs and regulatory initiatives have enhanced the detection and management of medication-related risks; however, significant challenges remain in underreporting of adverse events, limited pediatric clinical trials, age-related variability in drug response, and the management of polypharmacy among older adults. Strengthening pharmacovigilance infrastructure, promoting patient-centered care, integrating digital health technologies, and encouraging international collaboration are essential for improving medication safety across all healthcare settings. This review summarizes current evidence, identifies existing challenges, and discusses future perspectives for enhancing pharmacovigilance systems aimed at protecting pediatric and geriatric populations while supporting safer and more effective medication use.

Keywords

Medication Safety, Pharmacovigilance, Adverse Drug Reactions, Pediatric Pharmacovigilance, Geriatric Pharmacovigilance, Children, Older Adults, Polypharmacy, Medication Errors, Drug Safety, Patient Safety, Adverse Event Reporting, Healthcare Quality, Clinical Decision Support, Artificial Intelligence.

Introduction

Medication safety is a fundamental component of healthcare that aims to prevent medication-related harm while maximizing therapeutic benefits. Safe medication use involves appropriate prescribing, dispensing, administration, monitoring, and patient education throughout the medication-use process. Despite significant advances in pharmaceutical sciences and healthcare delivery, adverse drug reactions (ADRs), medication errors, and inappropriate medication use continue to pose major challenges worldwide, particularly among vulnerable populations such as children and older adults. These groups exhibit distinct physiological characteristics, altered pharmacokinetic and pharmacodynamic responses, and increased susceptibility to drug-related complications, making medication safety a global public health priority [1].

The World Health Organization (WHO) defines pharmacovigilance as the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems. Pharmacovigilance contributes significantly to improving patient safety by identifying previously unrecognized adverse events, monitoring the benefit-risk profile of medicines, and supporting regulatory decision-making. Global pharmacovigilance systems, including the WHO Programme for International Drug Monitoring coordinated by the Uppsala Monitoring Centre (UMC), have strengthened international collaboration in ADR reporting and signal detection, enabling healthcare professionals and regulatory agencies to respond promptly to emerging drug safety concerns [2,3].

Children represent a unique patient population because of continuous physiological growth and developmental changes that influence drug absorption, distribution, metabolism, and excretion. Neonates, infants, and adolescents require individualized dosing based on age, body weight, and organ maturity. Furthermore, limited pediatric clinical trials often result in off-label or unlicensed drug use, increasing the risk of unexpected ADRs and medication errors. Immature hepatic enzyme systems, developing renal function, and difficulties in dosage calculations further complicate pediatric pharmacotherapy, emphasizing the need for robust pharmacovigilance practices and continuous medication safety monitoring [4].

Similarly, older adults constitute one of the fastest-growing populations worldwide and experience a disproportionately high burden of medication-related problems. Age-associated physiological decline, multiple chronic diseases, cognitive impairment, frailty, and polypharmacy substantially increase the likelihood of adverse drug reactions, drug–drug interactions, and medication non-adherence. The use of potentially inappropriate medications, altered drug metabolism, and reduced renal and hepatic clearance further elevate the risk of hospitalization and morbidity due to medication-related harm. Consequently, geriatric pharmacovigilance has become an essential component of patient-centered healthcare aimed at optimizing therapeutic outcomes while minimizing preventable adverse events [5].

Medication errors remain a major cause of preventable patient harm across healthcare settings. Errors may occur during prescribing, dispensing, preparation, administration, or monitoring of medications. In pediatric patients, incorrect weight-based dose calculations and formulation-related issues are common causes of medication errors, whereas in older adults, complex medication regimens and polypharmacy contribute significantly to prescribing and administration errors. Effective pharmacovigilance systems facilitate early identification of these errors and support the implementation of preventive strategies to improve medication safety [6].

Recent technological advancements have transformed pharmacovigilance practices through the integration of electronic health records, clinical decision support systems, artificial intelligence, machine learning, big-data analytics, and mobile health applications. These technologies enhance ADR detection, improve signal generation, facilitate real-time safety monitoring, and strengthen post-marketing surveillance. Regulatory agencies such as the WHO, U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the Pharmacovigilance Programme of India (PvPI) continue to develop evidence-based guidelines and reporting frameworks to improve medication safety in special populations [7,8].

2. Foundations of Medication Safety

Medication safety refers to the prevention of avoidable harm associated with the use of medicines while ensuring optimal therapeutic outcomes. It encompasses every stage of the medication-use process, including prescribing, dispensing, preparation, administration, monitoring, and patient follow-up. Effective medication safety practices minimize the occurrence of adverse drug reactions (ADRs), medication errors, and inappropriate medication use, thereby improving the quality of healthcare and patient outcomes [9].

Children and older adults require special attention because physiological differences, altered drug metabolism, and age-specific clinical conditions influence both the efficacy and safety of medications. In pediatric patients, weight-based dosing and developmental changes increase the risk of dosing errors, whereas in older adults, polypharmacy, multiple comorbidities, and reduced organ function contribute to adverse drug events and drug–drug interactions [10,11].

The fundamental principles of medication safety include accurate patient identification, appropriate drug selection, individualized dose optimization, effective communication among healthcare professionals, continuous monitoring for adverse events, and patient or caregiver education. Medication reconciliation during transitions of care and adherence to evidence-based prescribing guidelines further reduce preventable medication-related harm [12].

Healthcare professionals, including physicians, pharmacists, nurses, and caregivers, play a vital role in ensuring medication safety through rational prescribing, patient counselling, prompt recognition of adverse events, and reporting of suspected ADRs to pharmacovigilance systems. A multidisciplinary approach supported by standardized safety protocols contributes significantly to reducing medication-related risks in vulnerable populations [13].

3. Fundamentals of Pharmacovigilance and Its Scope

Pharmacovigilance is the science and practice of detecting, assessing, understanding, and preventing adverse effects or any other medicine-related problems throughout a drug's lifecycle. It serves as an essential component of healthcare by ensuring that the benefits of medicines outweigh their potential risks. Pharmacovigilance extends beyond the identification of adverse drug reactions (ADRs) and includes medication errors, drug interactions, misuse, abuse, overdose, lack of therapeutic efficacy, and safety concerns associated with vaccines and biological products [14].

The primary objective of pharmacovigilance is to improve patient safety through continuous monitoring of medicines after their approval and marketing. Clinical trials often involve limited patient populations and controlled conditions, making post-marketing surveillance necessary to detect rare, delayed, or population-specific adverse events. Information collected from spontaneous reporting systems, electronic health records, observational studies, and patient registries contributes to identifying new safety signals and supports regulatory decision-making [15].

In pediatric and geriatric populations, pharmacovigilance is particularly important because these groups are frequently underrepresented in clinical trials and exhibit considerable variability in drug response. Continuous monitoring helps identify age-specific safety concerns, optimize dosage recommendations, and promote evidence-based prescribing practices. Collaboration among healthcare professionals, regulatory agencies, pharmaceutical industries, and patients strengthens pharmacovigilance activities and contributes to safer medication use [16].

Fig 1. core principle of medicine safety and pharmacovigilance

4. Medication Safety and Pharmacovigilance in Children

Children are considered a high-risk population for medication-related harm because their physiological functions change continuously during growth and development. Drug absorption, distribution, metabolism, and excretion differ significantly between neonates, infants, children, and adolescents, resulting in considerable variability in drug response. Consequently, pediatric pharmacotherapy requires individualized treatment, careful dose calculations, and continuous monitoring to ensure medication safety [17].

Many medicines prescribed in pediatric practice are used off-label or unlicensed due to limited clinical trials involving children. This lack of pediatric-specific evidence increases uncertainty regarding drug efficacy, optimal dosage, and long-term safety. Pharmacovigilance plays a crucial role in identifying adverse drug reactions (ADRs), evaluating benefit-risk profiles, and supporting safer prescribing practices in this population [18].

Medication errors remain one of the leading causes of preventable harm among children. Errors commonly occur during prescribing, dispensing, preparation, and administration because pediatric doses are frequently calculated according to body weight or body surface area. Decimal point errors, incorrect concentration of liquid formulations, and communication failures are frequent contributors to medication-related incidents [19].

Healthcare professionals, parents, and caregivers all contribute to pediatric medication safety. Appropriate counselling, standardized dosing devices, electronic prescribing systems, and routine ADR reporting improve treatment outcomes while reducing preventable adverse events. Continuous education and active participation in pharmacovigilance programs further strengthen medication safety in children [20].

Factor	Impact on Medication Safety	Citation
Immature organ function	Alters drug metabolism and elimination	[17]
Weight-based dosing	Increases risk of dosage calculation errors	[19]
Off-label drug use	Limited evidence on efficacy and safety	[18]
Liquid formulations	Risk of incorrect measurement and administration	[19]
Communication barriers	May delay recognition of ADRs	[20]
Limited pediatric clinical trials	Reduces availability of safety data	[18]

Table 4.1. Factors Affecting Medication Safety in Children

Medication Error	Possible Cause	Preventive Strategy	Citation
Incorrect dose calculation	Wrong body weight or decimal error	Double-check calculations	[19]
Wrong formulation	Similar drug preparations	Standardized prescribing	[20]
Incorrect administration	Measuring errors with liquid medicines	Use calibrated oral syringes	[20]
Wrong dosing interval	Miscommunication	Electronic medication schedules	[19]
Drug interaction	Multiple medications	Pharmacist medication review	[17]

Table 4.2. Common Medication Errors in Pediatric Patients

Pharmacovigilance Activity	Benefit	Citation
ADR reporting	Early detection of adverse reactions	[18]
Signal detection	Identifies previously unknown safety concerns	[17]
Post-marketing surveillance	Monitors long-term drug safety	[18]
Medication error reporting	Prevents recurrence of avoidable errors	[20]
Risk communication	Promotes safer prescribing practices	[17]

Table 4.3. Role of Pharmacovigilance in Pediatric Medication Safety

5. Medication Safety and Pharmacovigilance in Older Adults

Older adults represent one of the most vulnerable patient groups for medication-related harm due to age-associated physiological changes, multiple chronic diseases, and the frequent use of several medications simultaneously. Declining renal and hepatic function, reduced cardiac output, changes in body composition, and altered receptor sensitivity significantly influence drug absorption, distribution, metabolism, and excretion. These pharmacokinetic and pharmacodynamic alterations increase the risk of adverse drug reactions (ADRs), toxicity, and therapeutic failure, making individualized drug therapy essential in geriatric care [21].

Polypharmacy, commonly defined as the concurrent use of five or more medications, is highly prevalent among older adults. Although often necessary for managing multiple chronic conditions, polypharmacy substantially increases the likelihood of drug–drug interactions, drug–disease interactions, medication non-adherence, and inappropriate prescribing. Regular medication review, deprescribing when appropriate, and comprehensive clinical assessment are effective strategies to reduce medication-related risks in this population [22].

Potentially inappropriate medications (PIMs) remain a major concern in geriatric pharmacotherapy. Certain medicines may present greater risks than benefits because of increased susceptibility to sedation, cognitive impairment, falls, hypotension, bleeding, and renal toxicity. Evidence-based tools such as the Beers Criteria and STOPP/START criteria assist healthcare professionals in identifying medications that should be avoided or used cautiously in older adults, thereby improving prescribing quality and patient safety [23].

Pharmacovigilance plays a critical role in monitoring medication safety among older adults by facilitating the early detection of ADRs, evaluating benefit–risk profiles, and promoting rational medication use. Healthcare professionals should encourage ADR reporting, conduct periodic medication reconciliation, educate patients and caregivers, and utilize electronic prescribing systems to minimize medication errors. Strengthening geriatric pharmacovigilance through multidisciplinary collaboration contributes to safer, more effective, and patient-centered healthcare [24].

6. Risk Factors Affecting Medication Safety in Children and Older Adults

Medication safety is influenced by several patient-related, drug-related, and healthcare system-related factors. Children and older adults are particularly susceptible to medication-related harm because of physiological variability, complex therapeutic regimens, and the need for individualized treatment. Identifying these risk factors is essential for preventing adverse drug reactions (ADRs), minimizing medication errors, and improving therapeutic outcomes [25].

In children, immature organ development, age-dependent pharmacokinetic changes, and the frequent requirement for weight-based dosing increase the likelihood of dosing errors and unexpected ADRs. Off-label prescribing and the limited availability of pediatric formulations further complicate safe medication use. Inadequate communication between healthcare providers and caregivers may also contribute to medication misuse and poor adherence [26].

Among older adults, polypharmacy, multiple chronic diseases, cognitive decline, impaired vision, and reduced renal and hepatic function significantly increase the risk of medication-related complications. Age-related physiological changes alter drug response, while the use of potentially inappropriate medications increases the incidence of falls, hospitalization, and treatment failure. Poor medication adherence due to memory impairment or complex dosing schedules further compromises patient safety [27].

Healthcare system factors such as prescribing errors, incomplete medication reconciliation, inadequate monitoring, insufficient patient counselling, and underreporting of ADRs also contribute to medication-related harm in both age groups. Implementing electronic prescribing systems, clinical decision support tools, pharmacist-led medication reviews, and robust pharmacovigilance programs can substantially reduce these risks and improve medication safety [28].

7. Strategies to Improve Medication Safety and Pharmacovigilance

Improving medication safety requires a multidisciplinary approach involving healthcare professionals, patients, caregivers, regulatory authorities, and pharmaceutical industries. Effective pharmacovigilance systems combined with evidence-based medication safety practices can significantly reduce adverse drug reactions (ADRs), medication errors, and preventable hospitalizations in children and older adults. Continuous education, timely ADR reporting, medication reconciliation, and the use of health information technology are essential components of safer medication use [29].

Healthcare professionals should perform regular medication reviews, especially in patients receiving multiple medications or those with chronic illnesses. Patient and caregiver education regarding the correct use of medicines, possible adverse effects, and the importance of reporting unexpected reactions improves adherence and facilitates early identification of medication-related problems. The adoption of electronic prescribing systems and clinical decision support tools further minimizes prescribing and dispensing errors [30].

Pharmacovigilance programs encourage spontaneous ADR reporting, post-marketing surveillance, and signal detection to identify new safety concerns. Regulatory authorities utilize these data to update prescribing information, issue safety alerts, and implement risk minimization measures. Collaborative efforts among clinicians, pharmacists, nurses, patients, and national pharmacovigilance centers contribute substantially to improving medication safety across healthcare settings [31].

Strategy	Description	Expected Outcome	Citation
Medication reconciliation	Review medications during admission, transfer, and discharge	Reduces medication discrepancies	[29]
Electronic prescribing (e-Prescribing)	Computerized prescription generation	Minimizes prescribing errors	[30]
Clinical decision support systems	Alerts for allergies, interactions, and dosage	Improves prescribing accuracy	[30]
Medication review	Periodic assessment of all prescribed medicines	Reduces polypharmacy and inappropriate prescribing	[31]
Patient and caregiver education	Counselling on medicine use and ADR recognition	Improves adherence and early ADR detection	[29]
Standard treatment guidelines	Evidence-based prescribing practices	Enhances rational use of medicines	[31]

Table 7.1. Strategies for Improving Medication Safety

Healthcare Professional	Major Responsibilities	Citation
Physician	Rational prescribing, dose adjustment, ADR recognition	[29]
Pharmacist	Medication review, counselling, interaction monitoring, ADR reporting	[31]
Nurse	Safe medication administration and patient monitoring	[30]
Patient/Caregiver	Medication adherence and reporting adverse effects	[29]
Pharmacovigilance Centre	ADR collection, signal detection, risk communication	[31]

Table 7.2. Role of Healthcare Professionals in Medication Safety

Activity	Purpose	Benefit	Citation
Spontaneous ADR reporting	Collect suspected ADRs	Early detection of safety signals	[31]
Signal detection	Identify new medicine-related risks	Supports regulatory action	[31]
Post-marketing surveillance	Monitor medicines after approval	Detects rare and long-term ADRs	[29]
Risk management planning	Reduce medicine-associated risks	Improves benefit-risk balance	[30]
Safety communication	Disseminate drug safety information	Promotes safe medicine use	[31]

Table 7.3. Pharmacovigilance Activities for Medication Safety

8. Emerging Technologies and Future Perspectives in Medication Safety and Pharmacovigilance

Rapid advancements in digital health technologies have transformed pharmacovigilance by improving the detection, assessment, and prevention of medication-related problems. Artificial intelligence (AI), machine learning (ML), big-data analytics, electronic health records (EHRs), and mobile health (mHealth) applications are increasingly being integrated into pharmacovigilance systems to enhance medication safety. These technologies enable faster identification of adverse drug reactions (ADRs), improve signal detection, and support evidence-based regulatory decision-making [32].

Artificial intelligence and machine learning algorithms can analyze large volumes of healthcare data from spontaneous reporting systems, clinical databases, and scientific literature to identify previously unrecognized safety signals. Compared with conventional methods, AI-based systems improve the efficiency of pharmacovigilance by reducing manual workload and facilitating real-time safety monitoring. These technologies also assist in predicting high-risk patients who may develop medication-related complications, allowing healthcare professionals to implement preventive interventions [33].

Electronic health records have become valuable tools for medication safety by providing comprehensive patient information, including medication history, allergies, laboratory findings, and comorbidities. Integration of clinical decision support systems with EHRs generates automated alerts for drug interactions, duplicate therapy, contraindications, and inappropriate dosing, thereby reducing prescribing errors and improving patient outcomes. Such systems are particularly beneficial in pediatric and geriatric populations, where individualized drug therapy is essential [34].

Mobile health applications and online ADR reporting platforms have simplified adverse event reporting by enabling healthcare professionals and patients to submit reports directly to pharmacovigilance centers. These digital tools improve reporting rates, facilitate patient engagement, and enhance the quality of pharmacovigilance data. In addition, the use of social media monitoring and real-world evidence from healthcare databases provides valuable information regarding medicine safety in routine clinical practice [35].

Future pharmacovigilance is expected to become increasingly proactive through the integration of artificial intelligence, genomics, precision medicine, wearable health devices, and international data-sharing networks. Strengthening collaboration among regulatory agencies, healthcare professionals, researchers, and patients will further improve medication safety. Continued investment in digital infrastructure, standardized reporting systems, and healthcare professional training will be essential for developing efficient and patient-centered pharmacovigilance systems that ensure the safe use of medicines across all age groups [36].

9. Current Challenges and Future Perspectives in Medication Safety and Pharmacovigilance

Despite substantial progress in pharmacovigilance, several challenges continue to limit the effectiveness of medication safety programs, particularly in pediatric and geriatric populations. One of the most significant issues is the underreporting of adverse drug reactions (ADRs) by healthcare professionals and patients. Incomplete or delayed reporting reduces the ability of pharmacovigilance systems to identify new safety signals and implement timely regulatory interventions [37].

Another major challenge is the limited availability of clinical evidence in children and older adults. Pediatric patients are frequently excluded from large clinical trials due to ethical and practical concerns, while older adults with multiple comorbidities are often underrepresented. Consequently, many medicines are prescribed with limited age-specific safety data, increasing the risk of adverse events and inappropriate drug use [38].

Polypharmacy, increasing healthcare complexity, and variations in healthcare infrastructure further complicate medication safety. In many developing countries, inadequate awareness of pharmacovigilance, insufficient training of healthcare professionals, and lack of robust reporting systems hinder the effective monitoring of medicine-related risks. Differences in national pharmacovigilance policies and reporting practices also limit global data sharing and signal detection [39].

Future efforts should focus on strengthening pharmacovigilance systems through wider adoption of digital technologies, integration of artificial intelligence, expansion of real-world evidence, and improved international collaboration. Regular education and training programs for healthcare professionals, active patient participation, and harmonized regulatory guidelines will enhance ADR reporting and promote safer medication use. Continuous research involving pediatric and geriatric populations is also essential to generate high-quality evidence for rational prescribing and patient-centered healthcare [40].

CONCLUSION

Medication safety and pharmacovigilance are essential components of quality healthcare, particularly for children and older adults who are highly susceptible to medication-related harm. Age-specific physiological characteristics, altered pharmacokinetics and pharmacodynamics, polypharmacy, off-label drug use, and multiple comorbidities increase the risk of adverse drug reactions (ADRs) and medication errors in these vulnerable populations. Therefore, individualized therapy, careful medication monitoring, and evidence-based prescribing are critical for ensuring safe and effective treatment.

Pharmacovigilance plays a pivotal role in identifying, assessing, and preventing medicine-related risks through ADR reporting, post-marketing surveillance, signal detection, and risk management. Active participation of healthcare professionals, patients, caregivers, pharmaceutical industries, and regulatory authorities strengthens pharmacovigilance systems and promotes rational medicine use. The adoption of electronic health records, clinical decision support systems, artificial intelligence, and other digital health technologies has further enhanced the ability to detect and manage medication safety issues in real time.

Despite significant progress, challenges such as underreporting of ADRs, limited pediatric and geriatric clinical evidence, polypharmacy, and disparities in healthcare infrastructure continue to affect medication safety worldwide. Addressing these issues requires stronger regulatory frameworks, continuous professional education, increased public awareness, improved reporting systems, and international collaboration.

Overall, integrating comprehensive pharmacovigilance practices with patient-centered medication safety strategies will contribute to reducing preventable medication-related harm and improving therapeutic outcomes in children and older adults. Continued research and technological innovation will further strengthen global pharmacovigilance systems and support the safe, effective, and rational use of medicines across all healthcare settings.

REFERENCES

World Health Organization. Medication Without Harm: WHO Global Patient Safety Challenge on Medication Safety. Geneva: WHO; 2017.
World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO; 2002.
Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring. Uppsala, Sweden; 2024.
Turner MA, Catapano M, Hirschfeld S, Giaquinto C. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev. 2014;73:2–13. doi:10.1016/j.addr.2014.02.003.
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi:10.1046/j.1365-2125.2003.02007.x.
World Health Organization. Reporting and Learning Systems for Medication Errors: The Role of Pharmacovigilance Centres. Geneva: WHO; 2014.
European Medicines Agency. Good Pharmacovigilance Practices (GVP). European Medicines Agency; 2024.
Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India (PvPI): Guidance Document. Ghaziabad: IPC; 2023.
Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication without harm: WHO's third global patient safety challenge. Lancet. 2017;389(10080):1680–1681. doi:10.1016/S0140-6736(17)31047-4.
Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114–2120. doi:10.1001/jama.285.16.2114.
Maher RL Jr, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. doi:10.1517/14740338.2013.827660.
Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices. Arch Intern Med. 2012;172(14):1057–1069. doi:10.1001/archinternmed.2012.2246.
Alqenae FA, Steinke D, Keers RN. Prevalence and nature of medication errors and medication-related harm following discharge from hospital to community settings: a systematic review. Drug Saf. 2020;43(6):517–537. doi:10.1007/s40264-020-00918-3.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259. doi:10.1016/S0140-6736(00)02799-9.
Beninger P. Pharmacovigilance: an overview. Clin Ther. 2018;40(12):1991–2004. doi:10.1016/j.clinthera.2018.07.012.
Waller P, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2003;12(1):17–29. doi:10.1002/pds.746.
Smyth RL, Weindling AM. Research in children: ethical and scientific aspects of clinical trials in paediatrics. Lancet. 1999;354(Suppl 2):SII21–SII24. doi:10.1016/S0140-6736(99)90254-9.
Star K, Noren GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide: an exploratory study using the WHO global database. Drug Saf. 2011;34(5):415–428. doi:10.2165/11587540-000000000-00000.
Ghaleb MA, Barber N, Franklin BD, Wong ICK. The incidence and nature of prescribing and medication administration errors in paediatric inpatients: a systematic review. Drug Saf. 2010;33(12):1013–1030. doi:10.2165/11538210-000000000-00000.
Rashed AN, Wong ICK, Cranswick N, et al. Risk factors associated with medication safety in hospitalized children: a systematic review. Drug Saf. 2012;35(10):889–900. doi:10.2165/11635780-000000000-00000.
Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217–230. doi:10.1111/j.1472-8206.2007.00473.x.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230. doi:10.1186/s12877-017-0621-2.
O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing. 2015;44(2):213–218. doi:10.1093/ageing/afu145.
Davies EA, O'Mahony MS. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol. 2015;80(4):796–807. doi:10.1111/bcp.12596.
Aronson JK. Medication errors: definitions and classification. Br J Clin Pharmacol. 2009;67(6):599–604. doi:10.1111/j.1365-2125.2009.03415.x.
Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2001;52(1):77–83. doi:10.1046/j.0306-5251.2001.01407.x.
Marcum ZA, Gellad WF. Medication adherence to multidrug regimens in older adults. Clin Geriatr Med. 2012;28(2):287–300. doi:10.1016/j.cger.2012.01.008.
Sheikh A, Dhingra-Kumar N, Kelley E, Kieny MP, Donaldson LJ. The third WHO Global Patient Safety Challenge: tackling medication-related harm. Bull World Health Organ. 2017;95(8):546–546A. doi:10.2471/BLT.17.198002.
Institute for Safe Medication Practices (ISMP). Targeted Medication Safety Best Practices for Hospitals. ISMP Medication Safety Guidelines. 2022.
Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003;348(25):2526–2534. doi:10.1056/NEJMsa020847.
Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743–752. doi:10.1007/s00228-008-0475-9.
Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795–801. doi:10.7326/0003-4819-140-10-200405180-00009.
Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther. 2013;93(6):539–546. doi:10.1038/clpt.2013.24.
Classen DC, Phansalkar S, Bates DW. Critical drug–drug interactions for use in electronic health records and computerized physician order entry systems. J Am Med Inform Assoc. 2011;18(6):735–743. doi:10.1136/amiajnl-2011-000088.
Golder S, Norman G, Loke YK. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol. 2015;80(4):878–888. doi:10.1111/bcp.12746.
Wisniewski AFZ, Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469–490. doi:10.1007/s40264-016-0402-4.
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396. doi:10.2165/00002018-200629050-00003.
Rocchi F, Tomasi P. The development of medicines for children: Part of a series on pediatric pharmacology. Br J Clin Pharmacol. 2011;72(2):169–175. doi:10.1111/j.1365-2125.2011.03938.x.
Pirmohamed M. Pharmacovigilance: past, present and future. Drug Saf. 2006;29(5):353–358. doi:10.2165/00002018-200629050-00001.
Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449–460. doi:10.1586/17512433.2015.1053391.